Literature DB >> 11230147

Active repression and E2F inhibition by pRB are biochemically distinguishable.

J F Ross1, A Näär, H Cam, R Gregory, B D Dynlacht.   

Abstract

To understand mechanistically how pRB represses transcription, we used a reconstituted transcription assay and compared pRB activity on naked versus chromatin templates. Surprisingly, when pRB was directly recruited to a naked template, no transcriptional repression was observed. However, we observed active repression when the same promoter was assembled into chromatin. Histone deacetylases do not appear to play a role in this observed repression. Further experiments showed repression could occur after preinitiation complex assembly, in contrast with pRB inhibition of E2F, suggesting discrete mechanisms by which pRB directly inhibits an activator such as E2F or actively represses proximally bound transcription factors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11230147      PMCID: PMC312635          DOI: 10.1101/gad.858501

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  26 in total

1.  A mechanism for Rb/p130-mediated transcription repression involving recruitment of the CtBP corepressor.

Authors:  A R Meloni; E J Smith; J R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

2.  Establishment of irreversible growth arrest in myogenic differentiation requires the RB LXCXE-binding function.

Authors:  T T Chen; J Y Wang
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

3.  Role of the LXCXE binding site in Rb function.

Authors:  A Dahiya; M R Gavin; R X Luo; D C Dean
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

4.  Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF.

Authors:  H S Zhang; M Gavin; A Dahiya; A A Postigo; D Ma; R X Luo; J W Harbour; D C Dean
Journal:  Cell       Date:  2000-03-31       Impact factor: 41.582

5.  The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter.

Authors:  J Adnane; Z Shao; P D Robbins
Journal:  J Biol Chem       Date:  1995-04-14       Impact factor: 5.157

6.  Direct transcriptional repression by pRB and its reversal by specific cyclins.

Authors:  R Bremner; B L Cohen; M Sopta; P A Hamel; C J Ingles; B L Gallie; R A Phillips
Journal:  Mol Cell Biol       Date:  1995-06       Impact factor: 4.272

7.  Differential regulation of E2F transactivation by cyclin/cdk2 complexes.

Authors:  B D Dynlacht; O Flores; J A Lees; E Harlow
Journal:  Genes Dev       Date:  1994-08-01       Impact factor: 11.361

8.  RBP1 recruits both histone deacetylase-dependent and -independent repression activities to retinoblastoma family proteins.

Authors:  A Lai; J M Lee; W M Yang; J A DeCaprio; W G Kaelin; E Seto; P E Branton
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

9.  Mechanism of active transcriptional repression by the retinoblastoma protein.

Authors:  S J Weintraub; K N Chow; R X Luo; S H Zhang; S He; D C Dean
Journal:  Nature       Date:  1995-06-29       Impact factor: 49.962

10.  Physical interaction of the retinoblastoma protein with human D cyclins.

Authors:  S F Dowdy; P W Hinds; K Louie; S I Reed; A Arnold; R A Weinberg
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

View more
  10 in total

1.  Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase.

Authors:  L Vandel; E Nicolas; O Vaute; R Ferreira; S Ait-Si-Ali; D Trouche
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

2.  E2F mediates cell cycle-dependent transcriptional repression in vivo by recruitment of an HDAC1/mSin3B corepressor complex.

Authors:  Joseph B Rayman; Yasuhiko Takahashi; Vahan B Indjeian; Jan-Hermen Dannenberg; Steven Catchpole; Roger J Watson; Hein te Riele; Brian David Dynlacht
Journal:  Genes Dev       Date:  2002-04-15       Impact factor: 11.361

3.  p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes.

Authors:  Mary Truscott; Ryoko Harada; Charles Vadnais; François Robert; Alain Nepveu
Journal:  Mol Cell Biol       Date:  2008-03-17       Impact factor: 4.272

4.  Senescence is an endogenous trigger for microRNA-directed transcriptional gene silencing in human cells.

Authors:  Moussa Benhamed; Utz Herbig; Tao Ye; Anne Dejean; Oliver Bischof
Journal:  Nat Cell Biol       Date:  2012-02-26       Impact factor: 28.824

5.  F-box protein Skp2: a novel transcriptional target of E2F.

Authors:  L Zhang; C Wang
Journal:  Oncogene       Date:  2006-04-27       Impact factor: 9.867

6.  E2F integrates cell cycle progression with DNA repair, replication, and G(2)/M checkpoints.

Authors:  Bing Ren; Hieu Cam; Yasuhiko Takahashi; Thomas Volkert; Jolyon Terragni; Richard A Young; Brian David Dynlacht
Journal:  Genes Dev       Date:  2002-01-15       Impact factor: 11.361

7.  Functional antagonism between E2F family members.

Authors:  M V Frolov; D S Huen; O Stevaux; D Dimova; K Balczarek-Strang; M Elsdon; N J Dyson
Journal:  Genes Dev       Date:  2001-08-15       Impact factor: 11.361

8.  N-(4-Hydroxyphenyl) retinamide potentiated paclitaxel for cell cycle arrest and apoptosis in glioblastoma C6 and RG2 cells.

Authors:  Rajiv Janardhanan; Jonathan T Butler; Naren L Banik; Swapan K Ray
Journal:  Brain Res       Date:  2009-03-10       Impact factor: 3.252

9.  RBP1 family proteins exhibit SUMOylation-dependent transcriptional repression and induce cell growth inhibition reminiscent of senescence.

Authors:  Olivier Binda; Jean-Sébastien Roy; Philip E Branton
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

10.  Separation of anti-proliferation and anti-apoptotic functions of retinoblastoma protein through targeted mutations of its A/B domain.

Authors:  B Nelson Chau; Chris W Pan; Jean Y J Wang
Journal:  PLoS One       Date:  2006-12-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.